Literature DB >> 17009266

Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity.

Chee-Seng Yee1, Vernon Farewell, David A Isenberg, Athiveeraramapandian Prabu, Katharina Sokoll, Lee-Suan Teh, Anisur Rahman, Ian N Bruce, Bridget Griffiths, Mohammed Akil, Neil McHugh, David D'Cruz, Munther A Khamashta, Simon Bowman, Peter Maddison, Asad Zoma, Elizabeth Allen, Caroline Gordon.   

Abstract

OBJECTIVE: To test the interrater reliability of the revised British Isles Lupus Assessment Group 2004 (BILAG-2004) index for the assessment of systemic lupus erythematosus (SLE) activity.
METHODS: Patients with SLE were recruited from 11 centers. Two physician raters separately assessed the patients' disease activity using the BILAG-2004 index in routine clinical practice. Scores ranged from A (for very active disease) to E (for inactivity). Two reliability exercises were performed. Changes were made to the index after the first exercise (E1), and additional training was provided to the raters before the second exercise (E2). E1 and E2 involved 12 and 14 raters, respectively. Interrater reliability was assessed using kappa statistics and intraclass correlation coefficients. Levels of agreement and the extent of major disagreement were also examined. Major disagreement was defined as a score difference between raters of A versus C, D, or E or B versus D or E.
RESULTS: For each exercise, 97 patients were recruited. In E1, the mean age of the patients was 42.3 years (range 18.5-82.2 years), 89.7% were women, and 74.2% were white, 8.2% were Afro-Caribbean, and 13.4% were South Asian, and in E2, the mean age was 43.7 years (range 17.7-75 years), 90.7% were women, and 68% were white, 15.5% were Afro-Caribbean, and 11.3% were South Asian. The mean disease duration was 9.4 years (range 0-32.1 years) for patients in E1 and 10 years (range 0-34.8 years) in E2. There was improvement in the interrater reliability and the level of agreement from E1 to E2. Further improvement was achieved after removal of poorly performing items.
CONCLUSION: The BILAG-2004 index is a reliable tool to assess SLE activity. The use of a well-defined glossary and training of raters are essential to ensure the optimal performance of the index.

Entities:  

Mesh:

Year:  2006        PMID: 17009266     DOI: 10.1002/art.22162

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  29 in total

Review 1.  Top 10 things to know about lupus activity measures.

Authors:  Aikaterini Thanou; Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2013-06       Impact factor: 4.592

2.  Rituximab in the treatment of severe lupus myelopathy.

Authors:  Yan Ye; Jie Qian; Yueying Gu; Xiaoqing Chen; Shuang Ye
Journal:  Clin Rheumatol       Date:  2011-02-23       Impact factor: 2.980

3.  A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis.

Authors:  G Farina; D Lafyatis; R Lemaire; R Lafyatis
Journal:  Arthritis Rheum       Date:  2010-02

Review 4.  The need to define treatment goals for systemic lupus erythematosus.

Authors:  Kate Franklyn; Alberta Hoi; Mandana Nikpour; Eric F Morand
Journal:  Nat Rev Rheumatol       Date:  2014-07-22       Impact factor: 20.543

5.  An approach to validating criteria for proteinuric flare in systemic lupus erythematosus glomerulonephritis.

Authors:  Stacy Ardoin; Daniel J Birmingham; Paul L Hebert; Chack-Yung Yu; Brad H Rovin; Lee A Hebert
Journal:  Arthritis Rheum       Date:  2011-07

6.  Relationship between albuminuria and total proteinuria in systemic lupus erythematosus nephritis: diagnostic and therapeutic implications.

Authors:  Daniel J Birmingham; Brad H Rovin; Ganesh Shidham; Michael Bissell; Haikady N Nagaraja; Lee A Hebert
Journal:  Clin J Am Soc Nephrol       Date:  2008-05-01       Impact factor: 8.237

7.  TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus.

Authors:  Chang-Hee Suh; Brendan Hilliard; Sophia Li; Joan T Merrill; Philip L Cohen
Journal:  Arthritis Res Ther       Date:  2010-07-16       Impact factor: 5.156

8.  Numerical scoring for the BILAG-2004 index.

Authors:  Chee-Seng Yee; Lynne Cresswell; Vernon Farewell; Anisur Rahman; Lee-Suan Teh; Bridget Griffiths; Ian N Bruce; Yasmeen Ahmad; Athiveeraramapandian Prabu; Mohammed Akil; Neil McHugh; David D'Cruz; Munther A Khamashta; David A Isenberg; Caroline Gordon
Journal:  Rheumatology (Oxford)       Date:  2010-02-24       Impact factor: 7.580

9.  Serum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: Clinical relevance of HLA-F autoantibodies.

Authors:  V Jucaud; M H Ravindranath; P I Terasaki; L E Morales-Buenrostro; F Hiepe; T Rose; R Biesen
Journal:  Clin Exp Immunol       Date:  2015-12-16       Impact factor: 4.330

10.  British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus.

Authors:  Chee-Seng Yee; Vernon Farewell; David A Isenberg; Anisur Rahman; Lee-Suan Teh; Bridget Griffiths; Ian N Bruce; Yasmeen Ahmad; Athiveeraramapandian Prabu; Mohammed Akil; Neil McHugh; David D'Cruz; Munther A Khamashta; Peter Maddison; Caroline Gordon
Journal:  Arthritis Rheum       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.